JAN 18, 2021 7:00 AM PST

Arthritis Drug Approved for Critically Ill COVID Patients

WRITTEN BY: Tara Fernandez

Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mortality rates and accelerated recovery times in intensive care. 

The drug tocilizumab (Actemra) is an approved biologic medication for the treatment of rheumatoid arthritis. The drug works by blocking the inflammatory protein interleukin-6, or IL-6, to calm arthritis-induced joint swelling, pain, and other symptoms caused by inflammation. 

Researchers at the Imperial College London found that tocilizumab was also able to help COVID patients, reducing the mortality rate in critically ill individuals by around 10 percent and, on average, shortening their hospital stays by a week.

With the pandemic raging on in the new year, the list of existing treatments that have been tested to help COVID patients continues to grow. Unfortunately, except for the steroid treatment dexamethasone, few have been successful. 

Once the SARS-CoV-2 virus enters the body, infection typically manifests as influenza-like symptoms: cough, fever, and headaches. A subset of infected individuals spirals quickly into a state of potentially lethal hypoxemic respiratory failure—a condition caused by a massive surge of inflammatory factors in the body. These patients have markedly abnormal levels of IL-6, ferritin, and C-reactive proteins, among other molecules associated with the “cytokine storm.”

Tocilizumab’s life-saving effects are likely attributed to the drug’s ability to quench inflammation, specifically targeting IL-6. High circulating concentrations of this pro-inflammatory protein are associated with uncontrolled viral replication, a rapid decline in respiratory health, resulting in the need for mechanical ventilation, and even death. This led researchers to hypothesize that blocking IL-6 can help patients by halting the inflammatory cascade. 

The report from the REMAP-CAP trial indicates that the scientists may be on the right track. The ongoing clinical trial has enrolled nearly 4,000 patients in the U.K., with 350 of them receiving tocilizumab. Other pharmaceuticals targeting inflammation are also in the line-up for testing. 

 

Sources: The New England Journal of Medicine, Bloomberg.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 19, 2021
Cancer
Age of Colorectal Cancer Diagnosis Does not Affect Tumor Growth
AUG 19, 2021
Age of Colorectal Cancer Diagnosis Does not Affect Tumor Growth
Early-onset colorectal cancer progresses in the same way as average onset colorectal cancer. The corresponding study was ...
AUG 23, 2021
Microbiology
During a Chronic Viral Infection, Immune Cells May Suffer 'Exhaustion'
AUG 23, 2021
During a Chronic Viral Infection, Immune Cells May Suffer 'Exhaustion'
Several viruses are known to cause chronic infections, one is hepatitis C virus (HCV). Researchers studying these infect ...
SEP 06, 2021
Microbiology
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
SEP 06, 2021
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
HIV vaccines have remained elusive in part because the virus has a powerful ability to mutate, and there are so many str ...
SEP 14, 2021
Health & Medicine
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
SEP 14, 2021
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
As treatments and infection control practices surrounding COVID-19 continue to evolve, nanotechnological solutions are b ...
NOV 03, 2021
Plants & Animals
A Samoan Plant May Reduce Inflammation as Well as Ibuprofen
NOV 03, 2021
A Samoan Plant May Reduce Inflammation as Well as Ibuprofen
To the people of Samoa, the medicinal qualities of a tree known as matalafi are well known. Now scientists are bringing ...
NOV 21, 2021
Microbiology
Rare Genetic Variant Can Make People Susceptible to Bird Flu H7N9
NOV 21, 2021
Rare Genetic Variant Can Make People Susceptible to Bird Flu H7N9
Zoonosis is a serious health concern, as the COVID-19 pandemic has shown. Viruses that infect one species can acquire ge ...
Loading Comments...